A.R.T. Advisors’s Opus Genetics IRD Stock Holding History

A.R.T. Advisors’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-292	Closed	-$7K	–	1680
2019 Q1	$7K	Buy	+292	New	+$9.69K	﹤0.01%	1260
2018 Q4	–	Sell	-238	Closed	-$20K	–	1715
2018 Q3	$20K	Buy	+238	New	+$18.4K	﹤0.01%	1348

Other funds holding IRD

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

A.R.T. Advisors's IRD Position: Q2 2019 in Review

A.R.T. Advisors sold out of Opus Genetics (IRD) in Q2 2019, closing a stake of 292 shares — an estimated $7K sold.

A.R.T. Advisors first reported a position in IRD in Q3 2018 and held it in 2 quarters. The position peaked at $20K in Q3 2018. 16 funds tracked by Wall St. Rank hold IRD as of Q2 2019.

A.R.T. Advisors reported no remaining Opus Genetics position as of Q2 2019 after selling out during the quarter.
A.R.T. Advisors sold 292 Opus Genetics shares in Q2 2019, an estimated $7K.
A.R.T. Advisors first reported a position in Opus Genetics in Q3 2018 and held it in 2 quarters.
A.R.T. Advisors's Opus Genetics position peaked at $20K in Q3 2018.
16 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.